Synageva BioPharma (GEVA -5.5%) slips today after JP Morgan cut the shares to Neutral and lowers...

|About: Synageva BioPharma Corp. (GEVA)|By:, SA News Editor

Synageva BioPharma (GEVA -5.5%) slips today after JP Morgan cut the shares to Neutral and lowers its price target from $57 to $50. The firm cites concerns over enrollment challenges related to its ongoing Phase 3 trial of sebelipase alfa in late-onset LAL Deficiency, saying that awareness of the disease is fairly low, even among specialists, so patient identification could take a bit longer.